nutrition/micronutrients · clinical
Reference snapshot
This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.
Research focus · Curated October 26, 2026
Adequacy is not the same as enhancement.
Selected evidence, not a complete systematic review or physician-reviewed treatment guide. Study publication dates appear below; the curation date is not a claim that every finding is new.
25,871 adults; men ≥50 and women ≥55. Not recruited for vitamin-D deficiency, low bone mass, or osteoporosis.
Incident total fractures; median follow-up 5.3 years.
VITAL: total-fracture hazard ratio
Hazard ratio 0.98 (95% CI 0.89–1.08).
Not a trial of treating diagnosed deficiency. Does not settle every nutrient, life stage, or clinical indication.
Open study details, interpretation & review scope →Clinical lens: testing needs an indication
The Endocrine Society's 2024 prevention guideline suggests against routine vitamin-D testing and supplementation beyond dietary reference intakes in generally healthy adults under 75. It distinguishes adults 75 and older and other specific groups. Its scope excludes established reasons for testing or treatment; it is not a rule to ignore suspected deficiency.
B12: ask why a deficiency occurred
NIH ODS describes dietary shortfalls, impaired absorption, and medication effects as different causes. B12 supports neurological function and blood-cell formation. A clinician may use methylmalonic acid to clarify a borderline B12 result; kidney function affects its interpretation. Metformin can reduce B12 status, connecting supplement decisions to medication review.
B6: water-soluble does not mean unlimited
ODS links excess supplemental B6 to sensory neuropathy. A practical review should include every overlapping product, not just the bottle labeled B6. New tingling or numbness warrants clinical assessment rather than another supplement added to the stack.
Reading community claims
Claim-reading exercise, not prevalence evidence: an 'energy stack' may contain several products with the same nutrient. Record total ingredients, the reason for taking them, symptoms, and any clinician-defined reassessment plan. A better lab value is not automatically a better health outcome.
What research would change the picture?
Editorial research priorities: identify who benefits at a given baseline status; compare clinical outcomes, not just nutrient concentrations; and separate deficiency treatment from prevention trials in nutritionally adequate populations.
Claim ledger
These are declared editorial claim-to-source mappings. A mapping does not establish independent verification of the claim or its support. Citation controls open the corresponding source record.
Signal
Correcting clinically relevant deficiencies and meeting life-stage requirements can improve nutrient status and selected health outcomes.
Boundary
Nutrient status, a biomarker change, and a patient-important outcome are distinct, and benefit depends on baseline status, formulation, and population.
Not established
High-dose vitamin or mineral stacks are not established as universal nootropics, longevity treatments, or substitutes for diagnosing symptoms.
Mechanism map (working model)
A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.
Input or intervention
Dietary intake, absorption, storage, life stage, disease, medication, nutrient dose, and baseline status
Biological pathway
Cofactor, methylation, hematologic, endocrine, bone, immune, neuromuscular, and energy-metabolism pathways respond to adequacy or deficiency
Measurable signal
Validated nutrient or functional markers, symptoms, disease outcomes, dietary context, toxicity markers, and patient-important function
Boundary
Correcting a deficiency is not equivalent to improving a replete person's performance, cognition, or lifespan through megadosing.
Research appraisal checklist
Evidence to prioritize
Indication-specific clinical trials, patient-important outcomes, active comparators, safety monitoring, and follow-up long enough to test durability.
Outcome anchor
Separate symptom or biomarker movement from improved function, quality of life, disease control, or another outcome that matters to patients.
Main uncertainty
The main uncertainty is how much the result depends on diagnosis, product, dose, supervision, selection, and delivery setting.
What would change the conclusion
Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.
Minimum diligence questions
- Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
- Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
- Can the result be reproduced independently, and does it justify the level of risk being discussed?
Application and translation pathway
Current application boundary
Deficiency correction, life-stage nutrition, and indication-specific clinical care; broad high-dose optimization remains weakly supported.
Research and applied uses
- Deficiency and repletion trials
- Nutrient status and cognitive or functional outcomes
- Food-pattern, metabolomic, and personalized nutrition research
A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.
Define
Identify the suspected deficiency, indication, diet, symptoms, medication context, and validated test.
Replete
Use food adequacy or an indication-specific product at a documented dose and duration.
Monitor
Track symptoms, relevant laboratory measures, interactions, and toxicity rather than a single target number.
Translate
Judge benefit by function or clinical outcome and reassess whether continued supplementation is necessary.
Research and clinical readout
Research status
Vitamin and mineral supplementation spans deficiency treatment, pregnancy and life-stage needs, disease-specific care, food fortification, and consumer health optimization. The evidence is strongest when a deficiency or indication is defined; broad high-dose stacks often produce surrogate changes without proven improvements in longevity, cognition, or performance.
Signal confidence
Grade B (High for correcting clinically relevant deficiencies and meeting established life-stage needs; moderate for selected outcome-specific supplementation; low for megadose optimization and universal multivitamin claims.)
Key question
What deficiency or clinical outcome is being addressed, what is the validated test or indication, and what dose and follow-up balance benefit with toxicity?
Clinical perspective
The Endocrine Society's 2024 prevention guideline and NIH ODS B12/B6 references distinguish targeted care from routine optimization. The research focus above links the exact sources and their scopes.
Clinical uncertainty
Testing and treatment decisions depend on the clinical question; prevention guidance should not be applied as a deficiency-treatment rule.
Community patterns
Illustrative claims for appraisal, not a community survey: vitamin stacks marketed for energy, cognition, immunity, or longevity.
Common community failure mode
Treating a laboratory number as a universal target and overlooking overlapping ingredients or the cause of a symptom.
Where this is heading
Better deficiency phenotyping, food-pattern integration, pharmacogenomic and metabolomic context, and trials with patient-important outcomes may improve precision without turning nutrition into a dashboard chase.
What to track next
Vitamins and minerals are essential biological inputs, but the strongest case for supplementation is usually correcting deficiency or meeting a defined indication rather than taking high-dose stacks for generalized optimization.
Protocol and safety scaffold
Risk gate: Do not use high-dose vitamins or minerals to self-treat unexplained symptoms, pregnancy complications, anemia, neuropathy, thyroid symptoms, or bone disease without clinical evaluation.
Baseline first
- Define the suspected deficiency or indication, diet, symptoms, medications, pregnancy status, malabsorption risk, kidney or liver disease, and relevant laboratory method.
- List every overlapping product and choose one primary outcome such as correction of deficiency, symptom improvement, or a clinical marker with a defined target.
Implementation pattern
- Prefer food adequacy and cause-finding, then use indication-specific repletion at a documented dose and duration.
- Verify product identity, avoid duplicate ingredients, and schedule follow-up testing or symptom review when the nutrient and clinical context warrant it.
Monitor
- Symptoms, dietary intake, adherence, relevant labs, medication interactions, organ function, and the patient-important outcome.
- Whether the intervention improves function or health rather than only moving a level into a preferred consumer range.
Pause or stop rules
- Stop and seek care for severe gastrointestinal symptoms, confusion, weakness, neuropathy, palpitations, kidney-stone symptoms, allergic reaction, or abnormal laboratory results.
- Stop stacking or escalating when the cause of a symptom is unclear, the product is unverified, or the planned dose approaches an upper-limit concern.
Clinician gate
Use primary care, a registered dietitian, pharmacist, hematology, endocrinology, nephrology, or another relevant clinician for deficiency diagnosis, pregnancy, disease, or high-dose therapy.
Glossary connections
Controversies to monitor
Controversies
- Repletion of deficiency versus supplementation above adequacy.
- Biomarker normalization versus clinical benefit.
- Personalized testing, commercial panels, and the risk of medicalizing ordinary variation.
Core reference classes
Research classes
- VITAL fracture trial (2022)
- Endocrine Society prevention guideline (2024)
- NIH ODS B12 and B6 references
- 2025 multivitamin and B-vitamin evidence syntheses
Evidence timeline
Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.
Vitamin B12: Health Professional Fact Sheet
NIH Office of Dietary Supplements - Government clinical nutrition reference
B12 deficiency can involve inadequate intake or impaired absorption; metformin is one medication that can lower B12 status.
View source recordMultivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes
Ageing Research Reviews / PubMed - Rapid review of meta-analyses
A 2025 rapid review found outcome-specific signals for multivitamin and mineral use, including selected cognition and blood-pressure findings, but no established all-cause mortality or universal longevity benefit.
View source recordEfficacy of B Vitamin Supplementation on Global Cognitive Function in Older Adults
Nutrition Reviews / PubMed - Systematic review and meta-analysis of randomized trials
A 2025 meta-analysis of B6, B9, and B12 trials in older adults found a very small cognitive benefit after accounting for outliers, with the broader supplement claim still dependent on population and deficiency context.
View source recordRecommended Actions Based on Blood Lead Level
Centers for Disease Control and Prevention - Clinical public-health guidance
CDC guidance connects confirmed venous blood-lead levels with exposure investigation, nutrition and developmental support, public-health action, and specialist or chelation decisions at higher levels.
View source recordVitamin D for the Prevention of Disease: Guideline Resources
Endocrine Society - Clinical practice guideline
Distinguishes general-population disease prevention from established indications for vitamin-D testing or treatment.
View source recordClassification of Vitamin D Status Based on Vitamin D Metabolism
Nutrients / PubMed - Randomized controlled trial analysis
This randomized trial analysis examined whether additional vitamin-D metabolite measures identify people who benefit from supplementation, illustrating why dose and benefit depend on baseline status and the clinical question.
View source recordVitamin B6: Health Professional Fact Sheet
NIH Office of Dietary Supplements - Government clinical nutrition reference
Excess supplemental B6 can cause sensory neuropathy; water solubility is not a guarantee of safety.
View source recordSupplemental Vitamin D and Incident Fractures in Midlife and Older Adults
New England Journal of Medicine - Randomized placebo-controlled ancillary trial
VITAL tested fracture prevention in adults not selected for deficiency or osteoporosis.
View source recordTopic assessment
These questions test evidence interpretation and safety boundaries, not personal medical decisions.
1. What is the most defensible first question when evaluating Vitamin and Micronutrient Repletion?
Show answer and explanation
What outcome, evidence, and risk boundary are defined?
A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.
2. What would make a claim about Vitamin and Micronutrient Repletion more trustworthy?
Show answer and explanation
Replication with appropriate controls, context, and meaningful outcomes
Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.
Editorial update history
This log records what changed in the encyclopedia record and why the update matters for interpretation.
A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.
Added dedicated dossiers for vitamin and micronutrient repletion, peptide therapeutics and research-grade compounds, off-label medication repurposing, and compounded or online-sourced medications, with current nutrition evidence, human peptide pharmacology, FDA labeling resources, and product-quality boundaries.
Related record update: Multivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes; Efficacy of B Vitamin Supplementation on Global Cognitive Function in Older Adults; Classification of Vitamin D Status Based on Vitamin D Metabolism
Added a high-risk detoxification dossier connecting exposure source control, validated testing, CDC lead guidance, FDA chelation warnings, detox-diet evidence, sweat-excretion limits, and product-quality safeguards.
Related record update: Recommended Actions Based on Blood Lead Level
Linked evidence records
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
New England Journal of Medicine • Randomized placebo-controlled ancillary trial • Published: 2022-07-28 • Checked: Oct 26, 2026
VITAL tested fracture prevention in adults not selected for deficiency or osteoporosis.
How to interpret this record
Study at a glance
- Who was studied
- 25,871 adults; men ≥50 and women ≥55. Not recruited for vitamin-D deficiency, low bone mass, or osteoporosis.
- What was compared
- Vitamin D3 2,000 IU daily versus placebo within VITAL. Trial exposure, not a personal recommendation.
- What was measured
- Incident total fractures; median follow-up 5.3 years.
- Reported result
- Hazard ratio 0.98 (95% CI 0.89–1.08).
- How to read the numbers
- No demonstrated fracture reduction in this population; the interval includes no difference.
- Where this result stops
- Not a trial of treating diagnosed deficiency. Does not settle every nutrient, life stage, or clinical indication.
- Source and version
- PMID 35939577, indexed abstract; checked October 26, 2026.
What it supports
A randomized test of fracture prevention in this population.
Major limitations
Enrollment did not target deficiency or osteoporosis.
What it does not establish
That treating diagnosed deficiency is ineffective.
Vitamin D for the Prevention of Disease: Guideline Resources
Endocrine Society • Clinical practice guideline • Published: 2024-06-03 • Checked: Oct 26, 2026
Distinguishes general-population disease prevention from established indications for vitamin-D testing or treatment.
How to interpret this record
What it supports
Population-specific prevention guidance.
Major limitations
Scope excludes established indications for treatment or testing.
What it does not establish
One testing or supplementation rule for everyone.
Vitamin B12: Health Professional Fact Sheet
NIH Office of Dietary Supplements • Government clinical nutrition reference • Published: 2025-07-02 • Checked: Oct 26, 2026
B12 deficiency can involve inadequate intake or impaired absorption; metformin is one medication that can lower B12 status.
How to interpret this record
What it supports
Clinical context for B12 assessment and medication effects.
Major limitations
A reference, not a trial of a consumer stack.
What it does not establish
Universal benefits from a particular B12 formulation.
Vitamin B6: Health Professional Fact Sheet
NIH Office of Dietary Supplements • Government clinical nutrition reference • Published: 2023-06-16 • Checked: Oct 26, 2026
Excess supplemental B6 can cause sensory neuropathy; water solubility is not a guarantee of safety.
How to interpret this record
What it supports
Recognition of excess-intake neurological risk.
Major limitations
Individual exposure and context require clinical review.
What it does not establish
That a water-soluble vitamin is harmless at any intake.
Multivitamin and Mineral Use: A Rapid Review of Meta-Analyses on Health Outcomes
Ageing Research Reviews / PubMed • Rapid review of meta-analyses • Published: 2025 • Checked: Aug 17, 2026
A 2025 rapid review found outcome-specific signals for multivitamin and mineral use, including selected cognition and blood-pressure findings, but no established all-cause mortality or universal longevity benefit.
How to interpret this record
What it supports
Multivitamin and mineral interventions show outcome-specific signals in selected populations, including some cognition and blood-pressure outcomes.
Major limitations
The review combines different formulations, populations, doses, durations, and endpoints; pooled signals do not establish a universal healthspan or longevity effect.
What it does not establish
Taking a multivitamin does not prove longer life, broad disease prevention, or a need for high-dose stacking when nutritional adequacy is already present.
Efficacy of B Vitamin Supplementation on Global Cognitive Function in Older Adults
Nutrition Reviews / PubMed • Systematic review and meta-analysis of randomized trials • Published: 2025 • Checked: Aug 17, 2026
A 2025 meta-analysis of B6, B9, and B12 trials in older adults found a very small cognitive benefit after accounting for outliers, with the broader supplement claim still dependent on population and deficiency context.
How to interpret this record
What it supports
B-vitamin supplementation may produce a very small cognitive benefit in older adults in randomized evidence after accounting for influential studies.
Major limitations
The effect is population- and context-dependent, and heterogeneity, baseline status, diet, and outcome choice affect interpretation.
What it does not establish
B vitamins are not established as a general nootropic for people without deficiency or a substitute for evaluating cognitive symptoms.
Classification of Vitamin D Status Based on Vitamin D Metabolism
Nutrients / PubMed • Randomized controlled trial analysis • Published: 2024 • Checked: Aug 17, 2026
This randomized trial analysis examined whether additional vitamin-D metabolite measures identify people who benefit from supplementation, illustrating why dose and benefit depend on baseline status and the clinical question.
How to interpret this record
What it supports
Vitamin-D response can depend on baseline status and metabolic context, and additional laboratory measures may be useful research variables.
Major limitations
This was a short, population-specific randomized analysis; laboratory classification does not automatically predict long-term clinical benefit.
What it does not establish
A higher vitamin-D dose or a novel metabolite ratio is not a universal target, longevity treatment, or reason to ignore toxicity and clinical context.
Recommended Actions Based on Blood Lead Level
Centers for Disease Control and Prevention • Clinical public-health guidance • Published: 2025 • Checked: Aug 17, 2026
CDC guidance connects confirmed venous blood-lead levels with exposure investigation, nutrition and developmental support, public-health action, and specialist or chelation decisions at higher levels.
How to interpret this record
What it supports
CDC guidance supports confirmed blood-lead testing, exposure investigation, follow-up, nutrition and developmental support, and specialist consultation for higher levels.
Major limitations
Lead management is level-, age-, symptom-, and exposure-specific; pediatric guidance does not automatically transfer to every adult or environmental contaminant.
What it does not establish
A commercial hair, urine, or provoked test does not replace validated blood testing or establish a need for chelation.